Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer
Journal of Neuro-Oncology · 2026-05 · 177 (3)
DOI: 10.1007/s11060-026-05615-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 15.05.2026. Verfasst von Kelly Becht und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA. kelly.becht@yale.edu. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Radiosurgery, Brain Neoplasms, Lung Neoplasms. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Yale Cancer Center.
Abstract (Originalsprache)
PURPOSE: Stereotactic radiosurgery (SRS) is a commonly used alternative to whole-brain radiotherapy for patients with a limited burden of brain metastases from non-small cell lung cancer (NSCLC), but SRS receipt may be influenced by various sociodemographic factors. We sought to describe disparities in SRS receipt among adult patients with brain metastasis from NSCLC in the US. METHODS: We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to characterize disparities in SRS receipt. Analysis focused on adults diagnosed with brain metastases at the time of NSCLC diagnosis. Our outcome was receipt of SRS versus non-SRS radiotherapy. We developed a hierarchical multivariable logistic regression model to identify predictors of SRS receipt. RESULTS: Medicare beneficiaries living in rural versus urban locations (odds ratio [OR] 0.80, 95% confidence interval [CI] 0.67-0.96, p = 0.019) and with ≥ 3 versus no comorbidities (OR 0.77, 95% CI 0.66-0.91, p = 0.007) had lower odds of SRS receipt. Patient sociodemographic factors, including race and ethnicity, were not associated with SRS receipt. Before the 2014 "Choosing Wisely" guidelines, dual Medicare/Medicaid eligibility was associated with lower odds of SRS receipt (OR 0.74, 95% CI 0.57-0.96, p = 0.021). In the years after the guidelines, odds of SRS receipt was lower among rural patients (OR 0.79, 95% CI 0.62-1.00, p = 0.045) and those with ≥ 3 comorbidities (OR 0.76, 95% CI 0.61-0.94, p = 0.036). CONCLUSIONS: Nationally, we observed differences in SRS receipt in Medicare beneficiaries with a greater number of comorbidities and those living in rural areas. This data suggests that there may be subpopulations in need of targeted interventions to improve equitable SRS receipt.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA. kelly.becht@yale.edu.
- Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, USA.
- Coastal Radiation Oncology, Ventura, CA, USA.
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA.
- Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
- Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
Förderung
- Yale Cancer Center
Zitieren
APA
Becht, K., Lindsay, M. E., Soulos, P. R., Singh, C., Hansen, J. E., An, Y., Aneja, S., Goldberg, S. B., Chiang, V. L., & Park, H. S. (2026). Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer. Journal of Neuro-Oncology, 177(3). https://doi.org/10.1007/s11060-026-05615-2
Vancouver
Becht K, Lindsay ME, Soulos PR, Singh C, Hansen JE, An Y, et al. Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer. Journal of Neuro-Oncology. 2026;177(3). doi:10.1007/s11060-026-05615-2
BibTeX
@article{Becht2026,
author = {Becht, Kelly and Lindsay, Meghan E and Soulos, Pamela R and Singh, Charu and Hansen, James E and An, Yi and Aneja, Sanjay and Goldberg, Sarah B and Chiang, Veronica L and Park, Henry S},
title = {Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer},
journal = {Journal of Neuro-Oncology},
year = {2026},
volume = {177},
number = {3},
doi = {10.1007/s11060-026-05615-2}
}
EUVIMED